Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.
Naturally occurring antibodies directed against beta-amyloid (Abeta) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Abeta and Abeta(1-42) in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Abeta levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Abeta(1-42) levels. Antibodies against Abeta were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Abeta antibodies may modify Abeta and Abeta(1-42) levels, suggesting potential utility as a therapy for Alzheimer disease.
Dodel
Richard
R
Department of Neurology, Philipps University Marburg, Germany. ydu@iupui.edu
Hampel
Harald
H
Depboylu
Candan
C
Lin
Suizhen
S
Gao
Feng
F
Schock
Sabine
S
Jäckel
Steffi
S
Wei
Xing
X
Buerger
Katharina
K
Höft
Christine
C
Hemmer
Bernhard
B
Möller
Hans-Jürgen
HJ
Farlow
Martin
M
Oertel
Wolfgang H
WH
Sommer
Norbert
N
Du
Yansheng
Y
D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D016229:Amyloid beta-Peptides / Q000097:blood / Q000134:cerebrospinal fluid / Q000276:immunology*; D000906:Antibodies / Q000097:blood / Q000134:cerebrospinal fluid / Q000302:isolation & purification / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000188:drug therapy*; D010446:Peptide Fragments / Q000097:blood / Q000134:cerebrospinal fluid / Q000276:immunology
D016229:Amyloid beta-Peptides; D000906:Antibodies; D016756:Immunoglobulins, Intravenous; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)